Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Operating Expenses (2023 - 2025)

Immunocore Holdings (IMCR) has disclosed Operating Expenses for 3 consecutive years, with $121.5 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 17.73% to $121.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $440.3 million through Dec 2025, up 16.5% year-over-year, with the annual reading at $440.3 million for FY2025, 16.5% up from the prior year.
  • Operating Expenses hit $121.5 million in Q4 2025 for Immunocore Holdings, up from $110.4 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $121.5 million in Q4 2025 to a low of $69.1 million in Q1 2023.
  • Historically, Operating Expenses has averaged $93.9 million across 3 years, with a median of $93.2 million in 2024.
  • Biggest five-year swings in Operating Expenses: soared 39.93% in 2024 and later dropped 0.08% in 2025.
  • Year by year, Operating Expenses stood at $87.0 million in 2023, then grew by 18.57% to $103.2 million in 2024, then grew by 17.73% to $121.5 million in 2025.
  • Business Quant data shows Operating Expenses for IMCR at $121.5 million in Q4 2025, $110.4 million in Q3 2025, and $111.8 million in Q2 2025.